Time to go All-In on Celsion?
Celsion (CLSN) is a great story stock. It recently announced their Phase III trial results for liver cancer will be released by the end of January 2013. This will be a top-line release of a multinational, double-blind, placebo-controlled study of primary liver cancer. The results could make or break the company as its future pipeline is dependent on ThermoDox succeeding.
This upcoming catalyst is likely to have a huge impact on the company's valuation. The company has a current market cap of $287 million, but this will likely be drastically different by the end of the month. The CEO of Celsion has stated that this liver cancer treatment will have the potential to generate yearly revenues of $1 billion.
Mastery Bottom Line
Look for a good entry point before betting the farm on CLSN. Shares could dip down to touch the 50 day MA due to some investors not wanting to risk holding through the FDA results. A $7 - $7.50 share price would provide a great buying opportunity.
Best of the Blogs
Scanning and identifying the best blog entries every hour
- Chart Of The Day: Jeff Bezos "Value Creation" Edition | ZeroHedge
- Daily Scorecard | iBankCoin.com
- Neither the US Nor China Will be an Engine For Global Growth Next Year | ZeroHedge
- Smart People Listen To Radiohead, Dumb People Listen To Beyoncé, Study Finds | ZeroHedge
- Universities Feel the Gales of Creative Destruction | Financial Sense
- Stocks Shrug Off Ebola, Surge Most Since 2011, Still A Red October | ZeroHedge
- Are You DTF? | iBankCoin.com
The most relevant financial news and articles from the Internets
- Americans Can't Stop Working, And It's Becoming A... | Business Insider
- How To Get A Dancer's Body | Business Insider
- NFL WEEK 8: Our Official Predictions For Who Wins This Weekend | Business Insider
- Sweden calls off hunt for suspected submarine | Business Insider
- The 10 Most Important Things In The World Right Now | Business Insider
- Futures Tumble After Ebola Confirmed In New York, Amazon Whiffs On... | Business Insider
- Meet The Investor Funding Game-Changing Startups Run From College Dorms | Business Insider